Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
Patients with metastatic breast cancer with at least 2 brain metastases will receive
pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of
the brain lesions. Pembrolizumab will be infused a day before SRS at the standard dose of
200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable
toxicity.